MPNEatESMO2016

Wednesday, 12 October 2016

Overview of melanoma drugs

Displayed during poster discussions by Axel Hauschild on 10/10/2016.
photo credit Imogen Cheese





Posted by Violeta Astratinei at 06:23
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

Contributors

  • Bettina
  • Gilliosa SB
  • Unknown
  • Violeta Astratinei

Blog Archive

  • ▼  2016 (18)
    • ▼  October (18)
      • What cancer drugs will we be taking in 2020?
      • Plotting our next moves in ocular melanoma...a ver...
      • How to make 'cold' tumours such as metastatic ocul...
      • (Neo) Adjuvant Ipilimumab plus Nivolumab in Stage ...
      • Overview of melanoma drugs
      • Ipi 10 mg/kg vs ipi 3 mg/kg
      • Ipilimumab 10 mg/kg vs placebo in adjuvant setting
      • Dabrafenib/Trametinib update Combi v.
      • Combinations are the future
      • Joint Melanoma Simposium ESMO EORTC
      • Advocacy track - clinical trials
      • Adaptive licensing - MAPPs
      • Poster discussion session Melanoma
      • Melanoma abstracts
      • Session on Managed Entry Agreements
      • Ready to go!
      • The BMS sessions at ESMO - so just for THEIR treat...
      • The Melanoma Calendar for ESMO2016 is ready!
Simple theme. Powered by Blogger.